Shares of CELLECT BIOTECH/S (NASDAQ:APOP) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price target of $14.00 for the company and are anticipating that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned CELLECT BIOTECH/S an industry rank of 101 out of 255 based on the ratings given to its competitors.
Several research firms have recently weighed in on APOP. Zacks Investment Research downgraded CELLECT BIOTECH/S from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. HC Wainwright set a $14.00 target price on CELLECT BIOTECH/S and gave the company a “buy” rating in a research report on Friday, July 6th. Finally, ValuEngine raised CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th.
CELLECT BIOTECH/S (NASDAQ:APOP) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. equities analysts forecast that CELLECT BIOTECH/S will post -1 EPS for the current fiscal year.
An institutional investor recently bought a new position in CELLECT BIOTECH/S stock. Sabby Management LLC acquired a new stake in CELLECT BIOTECH/S (NASDAQ:APOP) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 243,980 shares of the company’s stock, valued at approximately $1,557,000. CELLECT BIOTECH/S comprises approximately 0.2% of Sabby Management LLC’s portfolio, making the stock its 23rd biggest position. Sabby Management LLC owned approximately 4.48% of CELLECT BIOTECH/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.22% of the company’s stock.
About CELLECT BIOTECH/S
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.